MARKET

IMGN

IMGN

ImmunoGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.02
+0.21
+3.53%
After Hours: 6.00 -0.02 -0.33% 19:47 12/04 EST
OPEN
5.72
PREV CLOSE
5.82
HIGH
6.24
LOW
5.72
VOLUME
2.86M
TURNOVER
--
52 WEEK HIGH
7.07
52 WEEK LOW
1.950
MARKET CAP
1.13B
P/E (TTM)
-14.7009
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 3d ago
ImmunoGen Announces Conference Call To Discuss Recent Updates For IMGN632 In Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia; Call Set For Dec. 7, 2020
ImmunoGen Announces Conference Call to Discuss Recent Updates for IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukemia ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of
Benzinga · 4d ago
The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions
Biotech stocks had a rather uneventful week, as the sector was seen mostly flatlining amid light trading volume ahead of the Thanksgiving holiday.
Benzinga · 5d ago
After Yesterday's Decline of 2.06%, Immunogen Inc Offers Investors Better Value
Immunogen Inc (NASDAQ:IMGN) traded in a range yesterday that spanned from a low of $5.20 to a high of $5.35. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $5.25 on volume of 910,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Comtex SmarTrend(R) · 11/25 18:04
ImmunoGen Announces Webcasts of Presentations at Upcoming Virtual Conferences
ImmunoGen Announces Webcasts of Presentations at Upcoming Virtual Conferences
Business Wire · 11/18 21:30
ImmunoGen Announces Webcasts of Presentations at Upcoming Virtual Conferences
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
BusinessWire · 11/18 18:30
Shares of IMGN Up 36.0% Since Uptrend Call on Shares
SmarTrend identified an Uptrend for Immunogen Inc (NASDAQ:IMGN) on October 6th, 2020 at $4.32. In approximately 1 month, Immunogen Inc has returned 36.04% as of today's recent price of $5.87.
Comtex SmarTrend(R) · 11/14 09:58
Immunogen Inc Set to Possibly Rebound After Yesterday's Selloff of 4.96%
Immunogen Inc (NASDAQ:IMGN) traded in a range yesterday that spanned from a low of $5.75 to a high of $6.20. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $5.84 on volume of 910,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Comtex SmarTrend(R) · 11/11 17:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMGN. Analyze the recent business situations of ImmunoGen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMGN stock price target is 9.07 with a high estimate of 14.00 and a low estimate of 5.50.
EPS
Institutional Holdings
Institutions: 314
Institutional Holdings: 151.83M
% Owned: 80.97%
Shares Outstanding: 187.53M
TypeInstitutionsShares
Increased
49
11.10M
New
51
5.13M
Decreased
68
12.76M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.87%
Pharmaceuticals & Medical Research
+1.71%
Key Executives
Chairman/Director
Stephen McCluski
President/Chief Executive Officer/Director
Mark Enyedy
Chief Financial Officer/Senior Vice President
Susan Altschuller
Senior Vice President
Anna Berkenblit
Senior Vice President
Stacy Coen
Senior Vice President
Theresa Wingrove
Vice President
Thomas Ryll
Independent Director
Stuart Arbuckle
Independent Director
Mark Goldberg
Independent Director
Dean Mitchell
Independent Director
Kristine Peterson
Independent Director
Richard Wallace
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IMGN
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of ImmunoGen, Inc. stock information, including NASDAQ:IMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMGN stock methods without spending real money on the virtual paper trading platform.